Abstract
Cancer chemotherapies, despite recent advances, are still limited because of their toxic effects and lack of efficacy on the nonproliferating fraction of malignant cells. The use of agents which could target specifically malignant cells might improve the selectivity of systemic chemotherapy. As an illustration of the promise of this concept, some monoclonal antibodies (MoAb) directed against a tumor-associated antigen have been used in vivo to treat cancer patients, including non-B, non-T acute lymphoblastic leukemias (CALL) [1], T-ALL [2], B and T cell lymphomas [3–7], chronic lymphocytic leukemias (CLL) [8–10], or solid tumors [11–13].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ritz, J., Pesando, J.M., Sallan, S.E., Clavell, L.A., Notis-McConarty, J., Rosenthal P., and Schlossman, S.F. (1981) Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood, 58, 141–152.
Bernard, A., Gosse, C., Pico, J., Favre, E., Raynal, B., Hayat, M., Lemerle, J., Charbord, P., and Boumsell, L. (1982) administration intraveineuse de l’anticorps monoclonal A50 chez un malade ayant une leucémie aiguë lymphoblastique à cellules T. Nouv. Presse Med., 11, 3173–3178.
Nadler, L.M., Stashenko, P., Hardy, R., Kaplan, W.D., Button, L.N., Kufe, D.W., Antman, K.H., and Schlossman, S.F. (1980) Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res., 40, 3147–3154.
Miller, R.A., Maloney, D.G., Warnke, R., and Levy, R. (1982) Treatment of B cell lymphoma with monoclonal antiidiotype antibody. N. Engl. J. Med., 306, 517–522.
Miller, R.A., and Levy, R. (1981) Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet, 2, 226–230.
Linch, D.C., Beverly, P.C., Newland, A., and Turnbull, A. (1983) Treatment of a low grade T cell proliferation with monoclonal antibody. Clin. Exp. Immunol., 51, 133–140.
Miller, R.A., Oseroff, A.R., Stratte, P.T., and Levy, R. (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood, 62, 988–995.
Dillman, R.O., Shawler, D.L., Sobol, R.E., Collins, H.A., Beauregard, J.C., Wormsley, S.B., and Royston, I. (1982) Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood, 59, 1036–1045.
Foon, K.A., Schroff, R.W., Bunn, P.A., Mayer, D., Abrams, P.G., Fer, M., Ochs, J., Bottino, G.C., Sherwin, S.A., Carlo, D.J., Herberman, R.B., and Oldham, R.K. (1984) Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood, 64, 1085–1093.
Dillman, R.O., Shawler, D.L., Dillman, J.B., and Royston, I. (1984) Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol., 2, 881–891.
Shen, J.W., Atkinson, B., Koprowski, H., and Sears, H. (1984) Binding of murine immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int. J. Cancer, 33, 465–468.
Schroff, R.W., Woodhouse, C.S., Foon, K.A., Oldham, R.K., Farrell, M., Klein, R.A., and Morgan, A.C. (1985) Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. J. Natl. Cancer Inst., 74, 299–306.
Houghton, A.N., Mintzer, D., Gordon-Caro, C., Welt, S., Fliegel, B., Vadhan, S., Carswell, E., Melamed, M.R., Oettgen, H.F., and Old, L.J. (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA, 82, 1242–1246.
Royston, I., Majda, J.A., Baird, S.M., Meserve, B.L., and Griffiths, J. (1980) Human T cell antigens defined by monoclonal antibodies. The 65,000 dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J. Immunol., 125, 725–731.
Burn, B.F., Warnke, R.A., Doggett, R.S., and Rouse, R.V. (1983) Expression of a T cell antigen (leu 1) by B cell lymphomas. Am. J. Pathol., 113, 165–171.
Al Saati, T., Laurent, G., Caveriviere, P., Rigal, F., and Delsol, G. (1984) Reactivity of leu 1 and T101 monoclonal antibodies with B cell lymphomas. Clin. Exp. Immunol., 58, 631–637.
Gros, O., Gros, P., Jansen, F.K., and Vidal, H. (1985) Biochemical aspects of immunotoxin preparation. J. Immunol. Methods, 81, 283–297.
Laurent, G., Pris, J., Farcet, J.P., Carayon, P., Blythman, H., Casellas, P., Poncelet, P., and Jansen, F.K. (1986) Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood, 67, 1680–1687.
Hertler, A.A., Schlossman, D.M., Borowitz, M.J., Laurent, G., Jansen, F.K., Schmidt, C., and Frankel, A.E. (1987) A phase I study of T101 ricin A-chain immunotoxin in refractory chronic lymphocytic leukemia, submitted for publication.
Spitler, L.E., personal communication.
Casellas, P., Canat, X., Fauser, A.A., Gros, O., Laurent, G., Poncelet, P., and Jansen, F.K. (1985) Optimal elimination of leukemia T-cells from human bone marrow with T101 ricin A-chain immunotoxin. Blood, 65, 289–297.
Shawler, D.L., Miceli, M.C., Wormsley, S.B., Royston, I., and Dillman, R.O. (1984) Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Res., 44, 5921–5927.
Bourrie, B., Casellas, P., Blythman, H., and Jansen, F.K. (1986) Study of the plasma clearance of antibody ricin A chain immunotoxins: Evidence for specific recognition sites on the A-chain that mediate rapid clearance of the immunotoxin. Eur. J. Biochem., 155, 1–10.
Laurent, G., Kuhlein, E., Casellas, P., Canat, X., Carayon, P., Poncelet, P., Correll, S., Rigal, F., and Jansen, F.K. (1986) Determination of sensitivity of fresh leukemia cells to immunotoxins. Cancer Res., 46, 2289–2294.
Akiyama, S., Seth, P., Pirker, R., Fitzgerald, D., Gottesman, M.M., and Pastan, I. (1985) Potentiation of cytotoxic activity of immunotoxins on cultured human cells. Cancer Res., 45, 1005–1007.
Casellas, P., Bourrie, B., Gros, P., and Jansen, F.K. (1984) Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxyl ionophores. J. Biol. Chem., 259, 9359–9364.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Laurent, G., Frankel, A.E., Hertler, A.A., Schlossman, D.M., Casellas, P., Jansen, F.K. (1988). Treatment of leukemia patients with T101 ricin A chain immunotoxins. In: Frankel, A.E. (eds) Immunotoxins. Cancer Treatment and Research, vol 37. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1083-9_27
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1083-9_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8419-2
Online ISBN: 978-1-4613-1083-9
eBook Packages: Springer Book Archive